Altimmune Inc. (NASDAQ:ALT) does about 5.34M shares in volume on a normal day but saw 2205644 shares change hands in Monday trading. The company now has a market cap of 834.94M USD and an enterprise value of about $833.98M. Its current market price is $27.25, marking an increase of 2.52% compared to the previous close of $26.58. The 52 week high reached by this stock is $35.10 whilst the lowest price level in 52 weeks is $1.51. The script in recent trading has seen the stock touch a high of $27.7796 and a low of $25.55.
Altimmune Inc. (ALT) has a 20-day trading average at $25.10 and the current price is -22.36% off the 52-week high compared with 1704.64% distance from its 52-week low. The 50-day simple moving average of the closing price is $15.03 and its 200-day simple moving average is $5.58. If we look at the stock’s price movements over the week, volatility stands at 12.52%, which increases to 22.04% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 62.24 to suggest the stock is neutral.
2 analysts observing the Altimmune Inc. (ALT) stock have set the 12-month price targets for the company’s shares at between $50.00 and $80.00. The consensus objective for the share price is $31.50, suggesting that the stock has a potential upside of 13.49% over the period. The median price target is 58.08% away from the current levels at $65.00.
FactSet Research has provided data showing that 2 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 0 advise that it is a overweight. 2 analysts have rated it as a buy and 0 have advised that investors hold their positions. The consensus recommendation rating is Buy and Wall Street’s advice is for investors to Moderate Buy the stock.
ROTH Capital resumed its price target at $13.
The current price level is 12.46%, 86.52%, and 399.70% away from its SMA20, SMA50, and SMA200 respectively, with the ALT price moving below the 50-day SMA on August 03. Altimmune Inc. (ALT) stock is up 21.49% over the week and 161.52% over the past month. Its price is 1341.80% year-to-date and 1089.96% over the past year.
The stock last released its quarterly earnings report for quarter ended 3/30/2020, with the company’s earnings per share (EPS) of -$0.26 above consensus estimates by $0.06. The company’s next earnings report is expected on 08/18/2020, with forecasts estimating quarterly EPS at -$0.4 and -$1.43 for whole year. ALT’s earnings per share are forecast to grow by 10.60% this year and -19.60% over next year. In addition, estimates put the company’s current quarterly revenue at an average of $1.12 million.
Its 12-month price target is $65.00. To reach the target analysts have set, the stock logically needs to grow 13.49 percent from here. Of course, the average price target is just what the average analysts believe a stock will be worth in the next 52 weeks, and is only one metric. There are analysts with lower targets than the average, including one bearish Wall Street research firm advocating investors to wait for the price to pull back to $50.00, given the recent momentum. And then, on the bullish side of things, one analyst is expecting the stock to peak at $80.00.
Outstanding shares total 15.11M with insiders holding 17.11% of the shares and institutional holders owning 8.38% of the company’s common stock. The company has a return on investment of -47.00% and return on equity of -46.20%. The beta has a value of 2.10. Price to book ratio is 9.84 and price to sales ratio is 163.71.
According to a U.S. Securities and Exchange Commission filing, Vanguard Total Stock Market Index has reduced its position in Altimmune Inc. (ALT) to 390,692 shares, mirroring a recent drop by -0.67%. Vanguard Total Stock Market Index dumped 2627.0 shares of Altimmune Inc. common stock bringing its total worth to about $4.18 million at the end of recent close, SEC documents show. Vanguard Total Stock Market Index isn’t the only investment manager who changed stakes and is followed by Vanguard Extended Market Index Fu, which sold off 0.0 shares to end up with 184,284 shares worth $1.97 million. Fidelity Extended Market Index Fu cut their holdings by 0.00% in the company over the course of the most recent quarter. It now holds a 0.26% position in Altimmune Inc. thanks to 56613.0 shares amounting to $0.61 million.